Ptc Therapeutics (PTCT) Other financing activities (2013 - 2026)

Ptc Therapeutics' Other financing activities history runs 14 years deep, the most recent figure standing at $6.4 million for Q1 2026.

• On a quarterly basis, Other financing activities fell 59.35% year-over-year to $6.4 million in Q1 2026; TTM through Mar 2026 was $83.8 million, a 83.07% decrease from a year earlier, with the FY2025 full-year figure at $93.1 million, down 61.5% from the prior year.
• Other financing activities retreated to $6.4 million in Q1 2026 per PTCT's latest filing, from $90.3 million in the prior quarter.
• Across five years, Other financing activities topped out at $241.8 million in Q2 2024 and bottomed at -$12.9 million in Q2 2025.
• The 5-year median for Other financing activities is $3.4 million (2023), against an average of $40.7 million.
• Across the five-year window, Other financing activities soared 87807.81% in 2024 and sank 105.34% in 2025, its largest moves.
• Year by year, Other financing activities stood at $3.3 million in 2022, then sank by 91.95% to $269000.0 in 2023, then surged by 87807.81% to $236.5 million in 2024, then plunged by 61.82% to $90.3 million in 2025, then plunged by 92.91% to $6.4 million in 2026.
• Per Business Quant, the three latest PTCT Other financing activities figures stand at $6.4 million (Q1 2026), $90.3 million (Q4 2025), and -$12.9 million (Q2 2025).